Opus Genetics, Inc. Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
Opus Genetics, Inc. (IRD) reported Research and Development Arrangement, Contract to Perform for Others, Compensation Earned of $1.50 million for the 12-month period ending 2003-12-31, per its 10-K filed 2019-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned · last filed 2019-03-07
- Opus Genetics, Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2003 was $1.50M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month |
|---|---|
| 2003-12-31 | $1.50M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |